title: A prospective, open-label study of milnacipran in the prevention of headache in patients with episodic or chronic migraine.
abstract: Migraine is a highly prevalent episodic and chronic neurological disorder that impacts otherwise healthy men and women in their most productive years. An anecdotal survey in our clinical practices suggested that milnacipran, a drug indicated for the treatment of fibromyalgia, reduced the incidence of headache in patients with migraine. In this 3-month, open-label, pilot study, 38 patients diagnosed with episodic migraine and 7 patients with chronic migraine maintained headache diaries to assess the effectiveness and tolerability of milnacipran in headache prevention. After a 1-month period to obtain baseline data, milnacipran treatment was initiated and doses were titrated up to 100 mg/day over 1 month. Maintenance therapy continued for an additional 3 months. The primary efficacy end point was change from baseline in the number of all headache days during the last 28 days of maintenance therapy analyzed, using last observation carried forward (LOCF). Change from baseline in migraine days during the last month of the maintenance period using LOCF was a secondary end point. Milnacipran 100 mg daily was associated with a significant reduction in headache (-4.2 days; P < 0.001) and migraine frequency (-2.2 days; P < 0.003). The adverse event profile was consistent with prior reports of milnacipran for the treatment of other conditions. However, compared with the recommended protocol, a more gradual increase in milnacipran dose was required to improve tolerability for some patients. The robust efficacy signal found in this study strongly suggests that a double-blind, placebo-controlled trial of milnacipran in migraine and chronic headache is warranted.
authors.affiliation: Dalessio Headache Center, Scripps Clinic, 10666 North Torrey Pines Rd. MS 313, La Jolla, CA, 92037, USA, emilyengel123@gmail.com.
authors.forename: Emily Rubenstein
authors.initials: ER
authors.lastname: Engel
authors.forename: David
authors.initials: D
authors.lastname: Kudrow
authors.forename: Alan M
authors.initials: AM
authors.lastname: Rapoport
mesh_terms: D000328:Adult; D003521:Cyclopropanes / Q000627:therapeutic use*; D004185:Disability Evaluation; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006261:Headache / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000150:complications*; D000078764:Milnacipran; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D003521:Cyclopropanes; D000078764:Milnacipran; D017367:Selective Serotonin Reuptake Inhibitors
references.citation: J Pharmacol Exp Ther. 2007 May;321(2):564-72
references.pmid: 17267580
references.citation: Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:41-6
references.pmid: 8923126
references.citation: Neuropsychiatr Dis Treat. 2013;9:709-20
references.pmid: 23717045
references.citation: Neurology. 2012 Apr 24;78(17):1337-45
references.pmid: 22529202
references.citation: J Pain Res. 2010 Mar 01;3:15-24
references.pmid: 21197306
references.citation: Headache. 2001 Jul-Aug;41(7):646-57
references.pmid: 11554952
references.citation: JAMA. 1984 Nov 9;252(18):2576-80
references.pmid: 6387197
references.citation: Pain Pract. 2012 Sep;12(7):541-9
references.pmid: 22300068
references.citation: Headache. 2005 Feb;45(2):144-52
references.pmid: 15705120
references.citation: Patient Relat Outcome Meas. 2010 Jul;1:107-18
references.pmid: 22915957
references.citation: Med Care. 1995 Apr;33(4 Suppl):AS264-79
references.pmid: 7723455
references.citation: CMAJ. 2010 Apr 20;182(7):E269-76
references.pmid: 20159899
references.citation: Ther Adv Musculoskelet Dis. 2010 Aug;2(4):201-20
references.pmid: 22870448
references.citation: J Neurosci. 1993 Mar;13(3):1167-77
references.pmid: 8382735
references.citation: Headache. 1976 Nov;16(5):238-45
references.pmid: 977330
references.citation: J Cereb Blood Flow Metab. 1992 Mar;12(2):223-9
references.pmid: 1312539
references.citation: Mol Pain. 2012 Jun 19;8:45
references.pmid: 22716121
references.citation: Clin Neurol Neurosurg. 2004 Dec;107(1):44-8
references.pmid: 15567552
references.citation: Cephalalgia. 1992 Apr;12(2):81-4
references.pmid: 1576648
references.citation: JAMA. 2004 Feb 25;291(8):965-73
references.pmid: 14982912
references.citation: Br J Pharmacol. 2007 Jul;151(6):737-48
references.pmid: 17471183
references.citation: J Rheumatol. 2009 Feb;36(2):398-409
references.pmid: 19132781
references.citation: Pain. 2000 Oct;88(1):41-52
references.pmid: 11098098
references.citation: Sleep. 1991 Dec;14(6):540-5
references.pmid: 1798888
references.citation: Neuropsychiatr Dis Treat. 2010 Sep 07;6:23-31
references.pmid: 20856597
references.citation: J Rheumatol. 2010 Apr;37(4):851-9
references.pmid: 20156949